Implementing the Deficit Reduction Act
Venue: Philladelphia
Location: Philladelphia, Pennsylvania, United States
Event Date/Time: Sep 20, 2007 |
Description
The DRA’s pricing transparency provision requires that CMS post the AMP of drug products on its Web site beginning July 1st of this year and to update the data quarterly. The availability of this formerly confidential pricing statistic will change the dynamics of the marketplace for brands with therapeutic alternatives or generic competition. It will make it even more challenging for multiple source drugs to sustain their price. The DRA also mandates that manufacturers report their AMP calculations to CMS on a monthly versus a quarterly basis. It is paramount that pharmaceutical and biotech companies devise a strategy for DRA implementation now, as the stakes are high. Don’t miss this opportunity to convene with your industry counterparts and with DRA experts!